Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx has announced new data to be presented at the 2024 American Transplant Congress from June 1-5 in Philadelphia. The data will highlight the clinical utility of CareDx's products, including AI integration in kidney transplant monitoring.
AI-derived AlloView results correlate with biopsy-proven kidney rejection, enhancing early rejection risk prediction. AlloSure Kidney’s longitudinal monitoring helps identify graft injury earlier and assesses rejection treatments effectively.
KOAR data show AlloSure-informed biopsies detect more acute rejections compared to traditional methods. AlloSure can potentially reduce unnecessary biopsies in cases of delayed graft function, avoiding up to 36% of biopsies.
Additionally, AlloMap and AlloSure indicate lower cancer risk post-heart transplant. Experts will present these findings at a symposium moderated by Dr. Kiran Khush.
CareDx has reiterated its position that it does not infringe Natera's '544 patent, emphasizing that Natera's injunction motion is irrelevant to its current business operations. The company clarified that it stopped using the previously alleged infringing AlloSure process since August 2023, switching to a new process believed to be non-infringing. The validity of the '544 patent is still under judicial review. CareDx further noted that previous claims by Natera on other patents were dismissed or found non-infringing. The ongoing litigation is not expected to affect CareDx's ability to provide its AlloSure and AlloMap services to transplant patients and clinicians.
CareDx (Nasdaq: CDNA), known as 'The Transplant Company,' has announced its participation in two upcoming investor conferences. The company's management will present at the Jefferies Global Healthcare Conference on June 6, 2023, at 11:30 AM PT / 2:30 PM ET and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2023, at 1:00 PM PT / 4:00 PM ET. These events provide opportunities for CareDx to discuss its precision medicine solutions for transplant patients and caregivers with investors. Interested parties can listen to the webcasts via the Events & Presentations section of the CareDx Investor Relations website.
CareDx announced findings from the SHORE study, which demonstrates that its HeartCare diagnostic tool outperforms donor-derived cell-free DNA (dd-cfDNA) testing alone in identifying acute cellular rejection (ACR) in heart transplant patients.
The study, involving over 2,700 patients across 67 centers, shows that dual-negative HeartCare results correlate with the lowest ACR incidence at 1.5%, while dual-positive results have the highest at 9.2%.
Cardiologists performed the fewest biopsies following dual-negative results (8.8%), significantly lower than dual-positive results (35.4%). The study highlights reduced biopsy rates and excellent clinical outcomes, with a 95% survival rate and 97% normal allograft function at two years post-transplant.
This significant study, published in The Journal of Heart and Lung Transplantation, underscores the benefits of dual molecular testing for heart transplant patient monitoring.
CareDx, Inc. (Nasdaq: CDNA) reported first quarter 2024 revenue of $72.0 million, with Testing Services revenue growing by 15% compared to the previous quarter. The company expanded payer coverage by 14 million lives, presented scientific advancements at ISHLT, and ended the quarter with approximately $216 million in cash and no debt. However, there was a 7% decrease in revenue compared to the first quarter of 2023, with a net loss of $16.7 million in the first quarter of 2024.
CareDx, Inc. (Nasdaq: CDNA) announced the award of 54,350 restricted stock units (RSUs) to 17 new employees as an inducement for employment. The RSUs were granted under the 2019 Inducement Equity Incentive Plan and vest over different periods based on the number of shares awarded.
CareDx, Inc. (Nasdaq: CDNA) will report financial results for the first quarter of 2024, focusing on healthcare solutions for transplant patients. The conference call will take place on May 9, 2024, providing insights for investors and interested parties.
Summary not available.
Summary not available.
Summary not available.